Correspondence 0001193125-24-118119 from Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619) (ELVN)
Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619)
Date: April 26, 2024 · CIK: 0001672619 · Accession: 0001193125-24-118119
AI Filing Summary & Sentiment
File numbers found in text: 333-278801
Letter
Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, Colorado 80301
April 26, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Enliven Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 18, 2024
File No. 333-278801
Acceleration Request
Requested Date: April 30, 2024
Requested Time: 4:00 p.m. Eastern Time,
or as soon thereafter as practicable
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enliven Therapeutics, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-278801) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Rachel Nagashima at (650) 849-3436.
Please direct any questions or comments regarding this acceleration request to Rachel Nagashima at (650) 849-3436.
[Signature Page Follows]
Very truly yours,
Enliven Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, Colorado 80301 April 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Enliven Therapeutics, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No. 333-278801 Acceleration Request Requested Date: April 30, 2024 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enliven Therapeutics, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-278801) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Rachel Nagashima at (650) 849-3436. Please direct any questions or comments regarding this acceleration request to Rachel Nagashima at (650) 849-3436. [Signature Page Follows] Very truly yours, Enliven Therapeutics, Inc. /s/ Samuel Kintz Samuel Kintz President and Chief Executive Officer cc: Tony Jeffries, Wilson Sonsini Goodrich & Rosati, Professional Corporation Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, Professional Corporation Rachel Nagashima, Wilson Sonsini Goodrich & Rosati, Professional Corporation [Signature Page to the Company’s Acceleration Request]